Ken Griffin Sutro Biopharma, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,100 shares of STRO stock, worth $3,948. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,100

Previous 200 950.0%

Holding current value

$3,948

Previous $0 Infinity%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.88 - $5.01 $1.46 Million - $2.54 Million	506,748 Added 31.28%	2,126,655 $7.36 Million
Q2 2024 Aug 14, 2024	BUY	$2.92 - $5.33 $3.74 Million - $6.82 Million	1,279,166 Added 375.41%	1,619,907 $4.75 Million
Q1 2024 May 15, 2024	BUY	$3.27 - $5.65 $682,828 - $1.18 Million	208,816 Added 158.28%	340,741 $1.93 Million
Q4 2023 Feb 14, 2024	BUY	$2.07 - $4.54 $172,505 - $378,345	83,336 Added 171.51%	131,925 $565,000
Q3 2023 Nov 14, 2023	BUY	$3.29 - $4.9 $66,658 - $99,278	20,261 Added 71.52%	48,589 $168,000
Q2 2023 Aug 14, 2023	SELL	$4.25 - $5.88 $1.28 Million - $1.77 Million	-300,840 Reduced 91.39%	28,328 $131,000
Q1 2023 May 15, 2023	BUY	$4.48 - $8.45 $937,063 - $1.77 Million	209,166 Added 174.3%	329,168 $1.52 Million
Q4 2022 Feb 14, 2023	SELL	$5.41 - $8.08 $985,106 - $1.47 Million	-182,090 Reduced 60.28%	120,002 $969,000
Q3 2022 Nov 14, 2022	SELL	$5.17 - $7.11 $1.62 Million - $2.23 Million	-313,607 Reduced 50.94%	302,092 $1.68 Million
Q2 2022 Aug 15, 2022	BUY	$3.41 - $8.95 $879,282 - $2.31 Million	257,854 Added 72.06%	615,699 $3.21 Million
Q1 2022 May 16, 2022	SELL	$7.78 - $15.31 $1.86 Million - $3.66 Million	-238,925 Reduced 40.04%	357,845 $2.94 Million
Q4 2021 Feb 14, 2022	SELL	$14.25 - $23.53 $1.04 Million - $1.71 Million	-72,873 Reduced 10.88%	596,770 $8.88 Million
Q3 2021 Nov 15, 2021	SELL	$16.88 - $22.38 $1.53 Million - $2.02 Million	-90,351 Reduced 11.89%	669,643 $12.7 Million
Q2 2021 Aug 16, 2021	SELL	$18.03 - $23.82 $3.91 Million - $5.16 Million	-216,626 Reduced 22.18%	759,994 $14.1 Million
Q1 2021 May 17, 2021	SELL	$20.29 - $27.54 $6.42 Million - $8.71 Million	-316,384 Reduced 24.47%	976,620 $22.2 Million
Q4 2020 Feb 16, 2021	BUY	$10.16 - $23.98 $740,450 - $1.75 Million	72,879 Added 5.97%	1,293,004 $28.1 Million
Q3 2020 Nov 16, 2020	SELL	$7.44 - $13.15 $382,401 - $675,883	-51,398 Reduced 4.04%	1,220,125 $12.3 Million
Q2 2020 Aug 14, 2020	SELL	$7.24 - $11.05 $2.01 Million - $3.07 Million	-277,831 Reduced 17.93%	1,271,523 $9.87 Million
Q1 2020 May 15, 2020	SELL	$6.19 - $12.16 $1.11 Million - $2.18 Million	-179,622 Reduced 10.39%	1,549,354 $15.8 Million
Q4 2019 Feb 14, 2020	SELL	$8.15 - $11.39 $6,748 - $9,430	-828 Reduced 0.05%	1,728,976 $19 Million
Q3 2019 Nov 14, 2019	BUY	$7.91 - $11.76 $11,540 - $17,157	1,459 Added 0.08%	1,729,804 $15.7 Million
Q2 2019 Aug 14, 2019	SELL	$9.69 - $12.23 $8,314 - $10,493	-858 Reduced 0.05%	1,728,345 $19.7 Million
Q1 2019 May 15, 2019	BUY	$8.8 - $11.87 $1,408 - $1,899	160 Added 0.01%	1,729,203 $0
Q4 2018 Feb 14, 2019	SELL	$8.69 - $14.85 $168,394 - $287,763	-19,378 Reduced 1.11%	1,729,043 $15.6 Million
Q3 2018 Nov 13, 2018	BUY	$15.0 - $15.2 $26.2 Million - $26.6 Million	1,748,421 New	1,748,421 $0

Others Institutions Holding STRO

# of Institutions

137

Shares Held

62.4M

Call Options Held

77.1K

Put Options Held

31.4K

View Full List

About SUTRO BIOPHARMA, INC.

Ticker STRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,161,500
Market Cap $98.1M
Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...

More about STRO

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account